Crossmark

Incidence and risk factors of serious infections occurred in patients with lung cancer following immune checkpoint blockade therapy

Published Online: 2025-02-20

Authors

Wang, Xiao https://orcid.org/0009-0009-5073-3759
Wu, Yu-xiao

Hu, Wei-ping

Zhang, Jing
Funding

Funding for this research was provided by:

Shanghai Top-Priority Clinical Key Disciplines Construction Project (NSFC(82270039), NSFC(82270039), NSFC(82270039), NSFC(82270039))
License Information

Text and Data Mining valid from 2025-02-20

Version of Record valid from 2025-02-20
More Information

Article History

Received: 12 June 2024

Accepted: 14 February 2025

First Online: 20 February 2025

Declarations

:

: This study achieved formal approval from the Clinical Research Unit (research approval number: KY2023572) and the Ethics Committee of Zhongshan Hospital (ethical number: B2024-009). This study was retrospective, and the Ethics Committee of Zhongshan Hospital waived the requirement of extra patient consent statements because written informed consent was obtained from all patients admitted to allow their medical records to be used in clinical observational studies. All identifying information was removed to protect patient confidentiality according to the requirement of the Ethics Committee of Zhongshan Hospital. This study was designed and conducted in accordance with the Declaration of Helsinki and local institutional standards.

: Not applicable.

: The authors declare no competing interests.

Document is current